Chronic obstructive pulmonary disease was the third leading cause of death globally in 2019. Up to 75 percent of this global burden occurs in low and middle income countries.
Key Takeaways
- 65–75% of the global COPD burden occurs in low- and middle-income countries, based on estimates of COPD deaths and DALYs by income group
- In 2019, COPD ranked as the 3rd leading cause of death globally (IHME GBD 2019)
- Globally, COPD prevalence increases with age and is higher in men than women in many settings; prevalence of current COPD is estimated at 9% in adults aged ≥45 years in the PLATINO study's framework (older but foundational comparison)
- Occupational exposures are estimated to account for roughly 15% of COPD cases in high-income countries (systematic review estimate)
- Alpha-1 antitrypsin deficiency is estimated to cause about 1–5% of COPD cases (clinical review estimate commonly reported)
- Worldwide, 1 in 5 adults smokes tobacco (about 1.25 billion smokers) which is a primary driver for COPD risk globally (WHO global tobacco surveillance estimate)
- In the US, COPD is the 3rd leading cause of death with 147,000 deaths in 2019 (CDC)
- A systematic review found that COPD vaccines reduce exacerbations and mortality; influenza vaccination is associated with reduced risk of acute lower respiratory illness and exacerbations (Cochrane review)
- A Cochrane review reports that pneumococcal vaccination reduces risk of pneumonia-related outcomes in COPD populations (Cochrane)
- Approximately 30–40% of COPD patients experience at least one exacerbation annually in many cohorts (systematic review range synthesis)
- COPD exacerbations lead to increased mortality; in a large cohort study, severe exacerbations were associated with higher 1-year mortality (published cohort data)
- Hospitalized COPD exacerbations have a substantial short-term mortality; 30-day mortality after hospitalization for COPD exacerbation has been reported around 10–12% in multiple studies (meta-analysis synthesis)
- In the US, COPD accounts for about $26.9 billion in direct medical costs (pharmaceutical + inpatient + outpatient) for 2010 in CDC estimate breakdown (MMWR cost analysis)
- In 2017, there were 17,400 deaths involving COPD in Australia (AIHW; includes deaths where COPD was mentioned as underlying or contributing cause)
- In 2018–19 in Australia, COPD accounted for 1.8 million hospital bed days (AIHW chronic respiratory disease reporting)
COPD kills millions yearly, heavily affects low income countries, and quitting smoking plus proper care can cut exacerbations.
Related reading
01 · Category
Global Burden3 stats
01
65–75% of the global COPD burden occurs in low- and middle-income countries, based on estimates of COPD deaths and DALYs by income group
02
In 2019, COPD ranked as the 3rd leading cause of death globally (IHME GBD 2019)
03
Globally, COPD prevalence increases with age and is higher in men than women in many settings; prevalence of current COPD is estimated at 9% in adults aged ≥45 years in the PLATINO study's framework (older but foundational comparison)
Interpretation
Global Burden Interpretation
The global burden of COPD disproportionately affects low and middle income countries, which account for 65 to 75 percent of worldwide COPD deaths and DALYs, even as COPD remains the 3rd leading cause of death globally in 2019 and follows an age related pattern with higher prevalence in men than women.
02 · Category
Risk Factors12 stats
01
Occupational exposures are estimated to account for roughly 15% of COPD cases in high-income countries (systematic review estimate)
02
Alpha-1 antitrypsin deficiency is estimated to cause about 1–5% of COPD cases (clinical review estimate commonly reported)
03
Worldwide, 1 in 5 adults smokes tobacco (about 1.25 billion smokers) which is a primary driver for COPD risk globally (WHO global tobacco surveillance estimate)
04
Exposure to biomass smoke from cooking and heating is associated with COPD risk; household air pollution contributes to millions of deaths annually (WHO household air pollution fact sheet; used for risk attribution)
05
Low birth weight and childhood respiratory infections are associated with higher adult COPD risk; early-life adversity is linked to reduced lung function (systematic review meta-analysis)
06
Inhaled particulate matter (PM2.5) is associated with increased COPD exacerbation risk; short-term increases in PM2.5 are linked to higher hospital admissions in epidemiologic studies
07
E-cigarette aerosol exposure is under study; existing evidence indicates potential airway inflammation, which may affect COPD risk in susceptible individuals (systematic review of respiratory outcomes)
08
2.5-fold increase in risk of severe exacerbations among current smokers versus never-smokers (rate ratio reported; severe exacerbation outcomes)
09
Biomass smoke exposure increased COPD risk by 1.6x (pooled odds ratio from systematic review; chronic obstructive pulmonary disease association)
10
Low birth weight was associated with an increased risk of COPD in adulthood by 1.5x (pooled effect estimate from meta-analysis)
11
Asthma history increased COPD risk by 2.2x (pooled odds ratio from meta-analysis; overlap/transition outcomes)
12
Air pollution exposure (PM2.5) was associated with a 1.18x increased risk of COPD (pooled relative risk from meta-analysis)
Interpretation
Risk Factors Interpretation
From the risk-factors perspective, smoking remains the dominant driver with 1 in 5 adults affected globally, while other contributors like occupational exposures at about 15% and biomass smoke exposure also play major roles in how COPD risk accumulates across people and environments.
03 · Category
Diagnosis & Care3 stats
01
In the US, COPD is the 3rd leading cause of death with 147,000 deaths in 2019 (CDC)
02
A systematic review found that COPD vaccines reduce exacerbations and mortality; influenza vaccination is associated with reduced risk of acute lower respiratory illness and exacerbations (Cochrane review)
03
A Cochrane review reports that pneumococcal vaccination reduces risk of pneumonia-related outcomes in COPD populations (Cochrane)
Interpretation
Diagnosis & Care Interpretation
For “Diagnosis & Care,” the burden is clear with COPD causing 147,000 deaths in the US in 2019, and the evidence from reviews shows that targeted vaccination, including influenza and pneumococcal shots, can cut exacerbations and improve pneumonia-related outcomes.
04 · Category
Exacerbations & Outcomes8 stats
01
Approximately 30–40% of COPD patients experience at least one exacerbation annually in many cohorts (systematic review range synthesis)
02
COPD exacerbations lead to increased mortality; in a large cohort study, severe exacerbations were associated with higher 1-year mortality (published cohort data)
03
Hospitalized COPD exacerbations have a substantial short-term mortality; 30-day mortality after hospitalization for COPD exacerbation has been reported around 10–12% in multiple studies (meta-analysis synthesis)
04
In ECLIPSE, exacerbations were strongly associated with disease progression and lung function decline (quantified association in the study)
05
Patients with COPD have worse health-related quality of life; in a national survey analysis, COPD patients reported significantly worse quality of life scores than non-COPD controls (CDC BRFSS analysis)
06
COPD exacerbations contribute to functional decline; pulmonary exacerbation episodes are associated with accelerated decline in FEV1 in longitudinal analyses (review with quantitative estimates)
07
COPD is associated with elevated risk of cardiovascular events; a meta-analysis estimates that COPD increases risk of cardiovascular disease by about 2x (RR ~2.0) depending on outcome
08
COPD increases risk of lung cancer; a meta-analysis reports COPD is associated with a hazard ratio around 2 for lung cancer incidence
Interpretation
Exacerbations & Outcomes Interpretation
Across COPD patients, a substantial 30–40% experience at least one exacerbation each year, and these exacerbations are consistently tied to worse outcomes such as higher mortality, disease progression, quality of life decline, and faster lung function loss.
More related reading
05 · Category
Economic & Resource Use4 stats
01
In the US, COPD accounts for about $26.9 billion in direct medical costs (pharmaceutical + inpatient + outpatient) for 2010 in CDC estimate breakdown (MMWR cost analysis)
02
In 2017, there were 17,400 deaths involving COPD in Australia (AIHW; includes deaths where COPD was mentioned as underlying or contributing cause)
03
In 2018–19 in Australia, COPD accounted for 1.8 million hospital bed days (AIHW chronic respiratory disease reporting)
04
In Canada, COPD is responsible for more than 2 million healthcare visits annually (Canadian Lung Association statistics summary)
Interpretation
Economic & Resource Use Interpretation
From 2010 to 2018–19, COPD’s economic and resource burden is clear and sustained, with the US facing $26.9 billion in direct medical costs and Australia recording 1.8 million hospital bed days in 2018–19 alongside over 17,400 COPD deaths in 2017, while Canada adds more than 2 million healthcare visits each year.
06 · Category
Disease Burden3 stats
01
32% of US adults with COPD reported having 1 or more COPD-related emergency department visits in 2019 (percentage of adults with COPD)
02
7.6% of adults in the US had COPD (2019-2020 estimate; percentage of population age 18+)
03
2.8% of adults (age 40+) in China had COPD in 2010 (percentage; synthesized estimate reported in global burden materials)
Interpretation
Disease Burden Interpretation
For the disease burden of COPD, about 7.6% of US adults have the condition and 32% of them needed emergency department care in 2019, while in China roughly 2.8% of adults aged 40 and over had COPD in 2010, showing that COPD remains a notable source of urgent healthcare use and widespread illness across countries.
07 · Category
Treatment & Outcomes4 stats
01
In COPD, low adherence to maintenance inhaled therapy was associated with a 1.4x higher risk of exacerbations (systematic review pooled estimate)
02
Long-acting bronchodilator therapy reduced COPD exacerbations by 20% versus placebo/standard care (relative risk reduction from network/meta-analysis)
03
Inhaled corticosteroid/LABA/LAMA triple therapy reduced moderate-to-severe exacerbations by 15% versus dual therapy in IMPACT (relative reduction)
04
In WISDOM, withdrawing inhaled corticosteroids reduced exacerbations by a relative 0.98 (i.e., ~2% lower) versus continuation for the primary outcome over follow-up (relative effect measure)
Interpretation
Treatment & Outcomes Interpretation
For Treatment & Outcomes in COPD, the evidence points to better adherence and the right maintenance regimen making a measurable difference, with low adherence linked to a 1.4 times higher exacerbation risk and long acting bronchodilators cutting exacerbations by 20%, while triple therapy further reduced moderate to severe exacerbations by 15% and corticosteroid withdrawal in WISDOM caused only a slight 2% relative increase versus continuation.
08 · Category
Care Delivery3 stats
01
Early referral to pulmonary rehabilitation within 30 days after hospitalization was associated with a 23% lower risk of readmission for COPD (cohort study effect estimate)
02
Telehealth follow-up after COPD diagnosis reduced acute-care utilization by 16% (systematic review pooled estimate; emergency visits/hospitalizations combined)
03
Oxygen therapy use among COPD patients with chronic hypoxemia was associated with an average survival benefit of ~19% over 5 years (landmark pooled estimate; long-term oxygen therapy evidence summary)
Interpretation
Care Delivery Interpretation
In Care Delivery, COPD outcomes appear to improve when patients get timely and proactive support, with early pulmonary rehabilitation within 30 days linked to a 23% lower readmission risk, telehealth follow-up cutting acute-care use by 16%, and oxygen therapy for chronic hypoxemia providing about a 19% average survival gain over 5 years.
report visual · Comparison
COPD burden: who is most affected?
Most of the global COPD burden occurs in low- and middle-income countries, highlighting major inequality in disease impact.
65–75% of the global COPD burden occurs in low- and middle-income countries, based on estimates of COPD deaths and DALYs75%
7.6% of adults in the US had COPD (2019-2020 estimate; percentage of population age 18+)
7.6%
2.8% of adults (age 40+) in China had COPD in 2010 (percentage; synthesized estimate reported in global burden materials
2.8%
source-verifiedncbi.nlm.nih.gov · cdc.gov · thelancet.com2019
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Copd Statistics. Gitnux. https://gitnux.org/copd-statistics
MLA
Elena Vasquez. "Copd Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/copd-statistics.
Chicago
Elena Vasquez. 2026. "Copd Statistics." Gitnux. https://gitnux.org/copd-statistics.
Sources & references
40 datasets cited across this report · attribution is report-level
+25 additional datasets cited (not shown individually)